Canonical and non-canonical adenosinergic pathways

Area of Science:

• Biochemistry
• Immunology
• Cell Biology

Background:

• Adenosine (ADO) is a key immunosuppressive molecule found in various human organs.
• Its production involves two distinct cell surface enzyme pathways: the canonical (CD39) and non-canonical (CD38, CD203a/PC-1).
• Both pathways converge at CD73 for the final conversion of AMP to ADO.

Purpose of the Study:

• To review the expression of ectoenzymes in adenosinergic pathways across different cell types.
• To summarize the physiological and pathological roles of these ectoenzymes and ADO.
• To discuss potential therapeutic strategies targeting ectoenzymes and ADO receptors.

Main Methods:

• Literature review of scientific findings on adenosinergic pathways.
• Analysis of ectoenzyme expression in regulatory and neoplastic cells.
• Synthesis of data on ADO's role in various biological contexts.

Main Results:

• Ectoenzymes of both adenosinergic pathways are expressed in diverse cell types, including immune regulatory subsets and cancer cells.
• These enzymes play significant roles in numerous physiological and pathological conditions.
• Specific inhibitors of ectoenzymes and ADO receptors show therapeutic potential.

Conclusions:

• The expression and function of adenosinergic pathway ectoenzymes are critical in cellular regulation and disease.
• Targeting these pathways offers promising avenues for novel therapeutic interventions.
• Further research into ectoenzyme modulation could lead to advanced treatments for various diseases.